Cost-Effectiveness of First-Line Immunochemotherapy Versus BRAF Plus MEK Inhibitors in BRAF V600E -Mutated Metastatic Lung Cancer.
Simple Summary: Patients with BRAFV600E-mutated metastatic lung cancer benefit from first-line BRAF plus MEK inhibitors and immune checkpoint inhibitor–chemotherapy. Nevertheless, a cost-effectiveness analysis comparing both treatments is lacking. This study suggests that despite the longer survival...
| Publicado en: | Current Oncology Vol. 33; no. 7; pp. 384 - 395 |
|---|---|
| Autores principales: | , , , , |
| Formato: | Journal Article |
| Publicado: |
MDPI
Jul2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |